| Literature DB >> 31257035 |
Aurélie Maran-Gonzalez1, Camille Franchet2, Raphaëlle Duprez-Paumier2, Martine Antoine2, Catherine Barlier2, Véronique Becette2, Anca Berghian2, Cécile Blanc-Fournier2, Eva Brabencova2, Emmanuelle Charafe-Jauffret2, Marie-Pierre Chenard2, Marie-Mélanie Dauplat2, Paul Delrée2, Clémence Fleury2, Christian Garbar2, Jean-Pierre Ghnassia2, Juliette Haudebourg2, Gaëtan MacGrogan2, Marie-Christine Mathieu2, Patrick Michenet2, Frédérique Penault-Llorca2, Bruno Poulet2, Yves Robin2, Pascal Roger2, Elisabeth Russ2, Isabelle Treilleux2, Alexander Valent2, Véronique Verriele2, Anne Vincent-Salomon2, Laurent Arnould2, Magali Lacroix-Triki2.
Abstract
Neoadjuvant therapy is an increasing treatment option in the management of breast cancer. The tumor response to neoadjuvant therapy, especially the pathological complete response, is a validated endpoint frequently used in clinical trials. However, there is still a lack of standardization for the surgical specimen management in the neoadjuvant setting. This leads to heterogeneity in the specimen handling and might lead to significant bias for the prognostic assessment of patients or in clinical trials. The GEFPICS group, composed of expert breast cancer pathologists, herein presents guidelines for the management of breast and axillary specimen before treatment (management of biopsy, items of the pathological report) and after neoadjuvant therapy (specimen handling, histological assessment of response, items of the pathological report and response grading systems).Entities:
Keywords: Breast cancer; Cancer du sein; Guidelines; Neoadjuvant; Néoadjuvant; Pathological response; Prélèvement; Recommandations; Réponse pathologique; Tissue sample
Mesh：
Substances：
Year: 2019 PMID： 31257035 DOI： 10.1016/j.annpat.2019.04.004
Source DB: PubMed Journal: Ann Pathol ISSN： 0242-6498 Impact factor: 0.407